TP53 and neoplasm: Regardless of the mutational heterogeneity within these malignant tumors, inactivating alterations in the TP53 gene are frequent changes detected in MPNST (up to 25%), which result in a loss of DNA damage response, increasing genomic instability and promoting tumor aggressiveness [36].